Weight Loss Medications: GLP-1 Agonists vs. Older Drugs

When it comes to losing weight, pills and injections have become a big part of the conversation. But not all weight loss medications are created equal. Two major groups dominate today’s options: the newer GLP-1 agonists and the older, more familiar drugs that have been around for decades. If you’re trying to decide which path makes sense for you, understanding the real differences - not just the marketing - is critical.

How GLP-1 Agonists Actually Work

GLP-1 agonists like Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) don’t just suppress your appetite. They mimic a natural hormone your body already makes called glucagon-like peptide-1. This hormone tells your brain when you’re full, slows down how fast food leaves your stomach, and helps your pancreas release insulin when needed. The result? You feel full sooner, eat less, and your blood sugar stays more stable.

These drugs were originally designed for type 2 diabetes. But in clinical trials, people lost far more weight than expected. Wegovy, for example, led to an average of 14.7% body weight loss in 36 weeks. Zepbound, which also targets a second hormone (GIP), showed even more - up to 20.9% over 72 weeks. That’s not just a few pounds. That’s a major shift in body composition.

Most GLP-1 agonists are injected once a week. Liraglutide (Saxenda) is the exception - it’s daily. There’s also an oral version of semaglutide called Rybelsus, but it’s only approved for diabetes, not weight loss. The injection route means you need to get comfortable with needles, but for many, the results outweigh the discomfort.

Older Weight Loss Drugs: What’s Still Out There

Before GLP-1 agonists took center stage, the market was filled with drugs like orlistat (Xenical, Alli), phentermine-topiramate (Qsymia), and naltrexone-bupropion (Contrave). These work in completely different ways.

Orlistat blocks fat absorption in your gut. About 30% of the fat you eat passes through undigested. That means greasy stools, frequent bathroom trips, and the need to take it with every meal. It’s not glamorous, and it doesn’t work for everyone.

Phentermine-topiramate (Qsymia) combines a stimulant (phentermine) with an anti-seizure drug (topiramate) that also reduces appetite. It can help people lose around 10% of their body weight. But it comes with risks - increased heart rate, tingling in hands and feet, and potential birth defects if taken during pregnancy.

Naltrexone-bupropion (Contrave) targets the brain’s reward system. It’s meant to reduce cravings and make food feel less rewarding. Studies show about 5-8% weight loss on average. It’s generally well-tolerated, but people with uncontrolled high blood pressure or seizure disorders shouldn’t take it.

All of these older drugs are taken as pills. No needles. No injections. That’s a big plus for people who hate needles or can’t manage daily injections.

Efficacy: The Numbers Don’t Lie

Let’s cut through the noise. When you compare head-to-head, GLP-1 agonists win by a wide margin.

A direct study cited by GoodRx found that Wegovy led to 16% weight loss, while Saxenda - another GLP-1 drug - only achieved 6%. That’s more than double the effect. Even compared to the best of the older drugs, GLP-1s are in another league.

Here’s a quick snapshot of average weight loss in clinical trials:

Real-world results are lower than trial numbers. A study from NYU Langone Health found that after six months, people on GLP-1 drugs lost only 4.7% on average. After a year, it was 7%. That’s still more than most older drugs, but it shows that sticking with treatment is harder than it sounds.

Cost: The Biggest Hurdle

Price is where the gap becomes a chasm.

GLP-1 agonists cost between $1,000 and $1,400 per month without insurance. That’s $12,000 to $16,800 a year. Even with manufacturer coupons, you’re still looking at $500-$1,000 in out-of-pocket costs annually. Many insurance plans only cover them if you have type 2 diabetes or a BMI over 40 - or over 35 with another health condition like high blood pressure or sleep apnea.

Older drugs? Not even close. Phentermine can cost as little as $10-$50 a month. Orlistat (Alli) is available over-the-counter for around $30-$60. Qsymia and Contrave are pricier, but still usually under $150 a month with insurance.

According to a KFF Health Tracking Poll in May 2024, 62% of people using GLP-1 drugs say they struggle to afford them. And 45% report being denied coverage outright because of strict insurance rules.

Side Effects: What You Might Not Be Prepared For

GLP-1 agonists aren’t magic. Nausea, vomiting, diarrhea, and constipation are common - especially when you’re starting or increasing your dose. Up to 50% of users experience these during the first few months. Some report severe bloating, gastroparesis (delayed stomach emptying), or even gallbladder problems.

Older drugs have side effects too. Orlistat causes oily stools and frequent bowel movements. Phentermine can raise heart rate and blood pressure. Contrave may cause headaches and dizziness. But none of them carry the same level of gastrointestinal disruption as GLP-1s.

Reddit communities like r/Wegovy and r/Ozempic are full of stories. Some users celebrate losing 78 pounds. Others describe months of nausea so bad they had to stop. One person wrote, "I lost 45 pounds, but I felt like I was constantly sick." That’s not uncommon.

Long-Term Use and Discontinuation

Here’s the hard truth: if you stop taking a GLP-1 agonist, you’ll likely regain most of the weight. Studies show 50% to 100% of lost weight comes back within a year of stopping.

That’s why many experts say these drugs aren’t a cure - they’re a tool. You need to combine them with lifestyle changes: better food choices, regular movement, stress management. Otherwise, the scale will climb back up.

And many people stop. A study in JAMA Surgery found up to 70% of patients discontinue GLP-1 therapy within a year. Reasons? Cost, side effects, or simply not losing enough.

Who Should Consider Which Option?

Here’s a simple guide:

• Choose a GLP-1 agonist if: You want the most significant weight loss possible, you’re okay with weekly injections, you can afford the cost or have good insurance, and you’re willing to stick with it long-term. These are especially helpful if you also have type 2 diabetes.
• Choose an older drug if: You can’t afford GLP-1s, hate needles, have insurance that won’t cover newer drugs, or need something with fewer GI side effects. Phentermine or orlistat might be a better starting point.

There’s no one-size-fits-all. Some people start with an older drug to see how their body responds. Others go straight to GLP-1s if their doctor believes they’re a strong candidate.

What’s Next? The Future of Weight Loss Drugs

The pipeline is full. Retatrutide, a triple-agonist targeting GLP-1, GIP, and glucagon, showed 24.2% weight loss in early trials. MariTide, a new antibody from Amgen, is now in Phase 3 testing. These could be even more effective.

But cost and access will remain issues. Right now, only 28% of commercial insurance plans cover GLP-1s for weight loss without strict restrictions. Until that changes, these drugs will remain out of reach for most.

And while surgery - like gastric bypass - still leads to 24% weight loss over two years, it’s invasive and not for everyone. GLP-1s offer a non-surgical alternative. But they’re not a replacement for surgery. They’re another tool in a bigger toolbox.

The bottom line? GLP-1 agonists are the most powerful weight loss drugs we’ve ever had. But they’re not simple. They’re expensive. They have real side effects. And they don’t work unless you keep taking them.

If you’re considering one, talk to your doctor. Ask about your insurance coverage. Ask about alternatives. Ask what happens if you stop. And be honest with yourself: Can you handle the cost? The injections? The nausea? The long-term commitment?

Because this isn’t about finding the "best" drug. It’s about finding the right one - for your body, your budget, and your life.